chimeric protein, oligomeric protein complex, polynucleotide, vector, transgenic cell, pharmaceutical composition, chimeric protein production method, method for producing an antibody, bacterial load reduction method, resistance induction method, vaccine, chimeric protein use, polyclonal antibody, method of prevention and use of antibody
Fernando Alberto Goldbaum,Giselle Ghersi,Leticia Veronica Bentancor,Maria Pilar Mejias,Marina Sandra Palermo,Martín Diego Linus Spatz,Patricio Oliver Craig,Vanesa Zylberman
申请号：
BR112015029776
公开号：
BR112015029776A2
申请日:
2014.05.26
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
Brucella lumazine synthase chimeras and beta subunit chimeras of ab5 toxins The present invention relates to chimeric polypeptides useful as immunogens for inducing immunoprotective responses and neutralizing antibodies against shiga toxin (stx) in mammals. More specifically, the present invention relates to chimeric polypeptides comprising a type 2 shiga toxin hemopentamer b-subunit monomer fused to the n-terminal of a brucella lumazine synthase monomer and oligomeric protein complexes formed from said chimeric polypeptides. The invention further relates to polynucleotides and vectors encoding said chimeric polypeptides, transgenic cells comprising said polynucleotides and vectors, and pharmaceutical compositions as a vaccine comprising said chimeric polypeptides and chimeric polynucleotides. Also within the scope of the invention are antibodies that bind to the chimeric polypeptides of the invention, a method for obtaining antibodies that specifically bind to type 2 shiga toxin subunit B and methods of reducing the bacterial burden of escherichi coli entero -hemorrhagic in mammals, which can be used to prevent, among other things, hemolytic uremic syndrome (hus).resumo quimeras de lumazina sintase de brucella e subunidade beta das toxinas ab5 a presente invenção refere-se aos polipeptídeos quiméricos úteis como imunógenos para induzir respostas imunoprotetoras e neutralizar anticorpos contra a toxina de shiga (stx) em mamíferos. mais especificamente, a presente invenção refere-se aos polipeptídeos quiméricos que compreendem um monômero da subunidade b hemopentamérica da toxina de shiga do tipo 2 fundida ao n-terminal de um monômero da lumazina sintase de brucella e aos complexos proteicos oligoméricos formados a partir dos ditos polipeptídeos quiméricos. a invenção refere-se ainda aos polinucleotídeos e vetores que codificam os ditos polipeptídeos quiméricos, às células transgênicas compreendendo os ditos polinucleotídeos e vetores, e às composições farmacêuticas,
